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Low Mr phosphotyrosine-protein phosphatase is in-
volved in the regulation of several tyrosine kinase growth
factor receptors. The best characterized action of this en-
zyme is on the signaling pathways activated by platelet-
derived growth factor, where it plays multiple roles. In this
study we identify tyrosine-phosphorylated caveolin as a
new potential substrate for low Mr phosphotyrosine-pro-
tein phosphatase. Caveolin is tyrosine-phosphorylated in
vivo by Src kinases, recruits into caveolae, and hence reg-
ulates the activities of several proteins involved in cellular
signaling cascades. Our results demonstrate that caveolin
and low Mr phosphotyrosine-protein phosphatase coimmu-
noprecipitate from cell lysates, and that a fraction of the
enzyme localizes in caveolae. Furthermore, in a cell line
sensitive to insulin, the overexpression of the C12S domi-
nant negative mutant of low Mr phosphotyrosine-protein
phosphatase (a form lacking activity but able to bind sub-
strates) causes the enhancement of tyrosine-phosphoryl-
ated caveolin. Insulin stimulation of these cells induces a
strong increase of caveolin phosphorylation. The localiza-
tion of low Mr phosphotyrosine-protein phosphatase in
caveolae, the in vivo interaction between this enzyme and
caveolin, and the capacity of this enzyme to rapidly dephos-
phorylate phosphocaveolin, all indicate that tyrosine-phos-
phorylated caveolin is a relevant substrate for this
phosphatase.
Caveolin is a small integral membrane protein and the prin-
cipal component of caveolae membrane domains in vivo (1).
Caveolae are plasma membrane-attached vesicular organelles
that have a characteristic diameter in the 50–100-nm range (2,
3). Although caveolae are present in most cells, they are par-
ticularly abundant in terminally differentiated cells such as
adipocyte, endothelial, and skeletal muscle cells. Recent stud-
ies have revealed the presence of at least three mammalian
caveolin subtypes, caveolin-1, caveolin-2, and caveolin-3, with
different tissue distribution (see Ref. 4, and references therein).
Different from the role originally proposed, i.e. as a protein that
organizes the caveolae structure and accumulates many sig-
naling molecules, a new role for caveolin as a regulator of
transmembrane signaling has been suggested by recent data.
Several research teams have demonstrated that caveolin is
able to recognize and recruit into caveolae, and to regulate the
activities of several proteins involved in cellular signaling cas-
cades, such as the heterotrimeric G-proteins, Src kinases, ni-
tric-oxide synthase, epidermal growth factor, and platelet-de-
rived growth factor receptors, as well as protein kinase C (see
Ref. 4, and references therein). The interaction between caveo-
lin and other proteins is mediated through a short stretch of
the membrane-proximal region (or caveolin scaffolding do-
main), encoded by residues 82–101, which recognizes and binds
proteins containing the sequence motif cXcXXXXc or
cXXXXcXXc, where c is an aromatic residue (5).
Previous studies have demonstrated that caveolin is phos-
phorylated on tyrosine by the oncogenic viral Src kinase (v-
Src), and that caveolin is associated with normal cellular Src
(c-Src) and other Src family tyrosine kinases (6, 7).
Low Mr phosphotyrosine-protein phosphatase (LMW-PTP)
1
is expressed as two molecular isoforms in mammalian species.
These isoforms originated from two different mRNAs produced
through an alternative splicing mechanism (8). In addition to
mammals, the enzyme is expressed in a sole molecular form in
several microorganism species (9–12). It belongs to the large
family of protein-tyrosine phosphatases (PTPs) that are di-
vided into four subfamilies: the tyrosine-specific phosphatases,
the VH1-like dual specificity phosphatases, the cdc25 phos-
phatases, and the low molecular weight phosphatases. All
PTPs have the active site signature sequence CXXXXXR, and
all share the same catalytic mechanism (13). Arginine is in-
volved in substrate binding, whereas cysteine performs the
nucleophilic attack on the substrate phosphorus atom, produc-
ing a covalent enzyme-phosphate intermediate, whose hydrol-
ysis is the limiting step of the catalytic process. An aspartic
acid residue assists the nucleophilic reaction by donating a
proton to the leaving group in the transition state.
Although the function of LMW-PTP in microorganisms is
still debated (10, 12), several papers produced in the last few
years have indicated that the enzyme participates in the tyro-
sine kinase receptor function (14–18). Specifically, the enzyme
is involved in the down-regulation of PDGF and insulin recep-
tors (14–16). In the case of the PDGF receptor, the overexpres-
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as a dominant-negative (dn) mutant (C12S), a form able to bind
substrates but catalytically inactive) produces opposite pheno-
typic effects; the wild type enzyme decreases cell growth rate,
whereas the dn mutant increases it. The analysis of this action
mechanism demonstrated that LMW-PTP binds and dephos-
phorylates the activated receptor in vivo. In particular, LMW-
PTP is involved in pathways that regulate the transcription of
the early genes myc and fos in response to growth factor
stimulation.
Recent reports have also demonstrated that LMW-PTP is
localized constitutively in cytosol and cytoskeleton, and that
upon growth factor stimulation c-Src is able to bind and phos-
phorylate only the cytoskeleton-associated enzyme. As a con-
sequence of its phosphorylation, LMW-PTP increases its activ-
ity about 20-fold, and this strongly influences both cellular
adhesion and migration. The target of cytoskeleton-associated
LMW-PTP is p190Rho-GAP, which is phosphorylated on tyro-
sine after PDGF-stimulation (19). In the case of insulin signal-
ing, the specific involvement of the enzyme in the Src pathway
has been demonstrated. Overexpression of the dn form of the
enzyme also influences glucose uptake and glycogen synthesis
upon insulin stimulation (16).
Finally, the involvement of LMW-PTP in the regulation of
other growth factor receptors has been reported. Stein et al.
(20) have found that LMW-PTP is involved in the ephrine-B1
receptor function; Rigacci et al. (18) and Rovida et al. (17),
respectively, have shown that the fibroblast growth factor re-
ceptor and the macrophage colony-stimulating factor receptor
functions are regulated by LMW-PTP.
In this paper we demonstrate that tyrosine-phosphorylated
caveolin is a potential physiological substrate for LMW-PTP.
EXPERIMENTAL PROCEDURES
Materials—Human recombinant LMW-PTP was prepared as de-
scribed previously (21). Monoclonal anti-phosphotyrosine (PY-20) and
polyclonal anti-caveolin (sc-894) antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA). Monoclonal anti-phosphocaveolin (PY14)
antibody was purchased from Transduction Laboratories (Lexington,
KY). The sc-894 antibody is raised against a peptide corresponding to
amino acids 2–21 mapping at the amino terminus of caveolin-1, while
the PY-14 monoclonal antibody is raised against a tyrosine-phosphory-
lated peptide corresponding to amino acids 9–18 mapping at the amino
terminus of caveolin-1. Rabbit polyclonal anti-LMW-PTP antibody was
produced in our laboratory. Protein A-Sepharose beads was from
Sigma. Soluble PTP-1B (recombinant glutathione S-transferase fusion
protein corresponding to full-length human PTP-1B) was purchased
from Upstate Biotechnology (Lake Placid, NY). Electrophoresis re-
agents were purchased from Bio-Rad. Enhanced chemiluminescence
(ECL) reagents were from Amersham Pharmacia Biotech. All other
reagents were the purest commercially available.
Protein Determination—Protein concentration was assayed by the
bicinchoninic acid method (BCA kit) purchased from Sigma.
Cell Cultures and Transfections—NIH-3T3 fibroblasts, stable trans-
fected NIH-3T3 cell lines overexpressing wild type LMW-PTP or its
C12S dn mutant (prepared as described by Chiarugi et al. (Ref. 22)), and
H-end endothelial cells (kindly provided from F. Bussolino, University
of Torino, Italy) were grown at 37 °C in a humidified atmosphere
containing 5% CO2 in Dulbecco’s modified Eagle’s medium, supple-
mented with 10% fetal calf serum and antibiotics (penicillin, strepto-
mycin). NIH-3T3IR (a cell line overexpressing insulin receptor; Ref. 23)
were kindly provided by AR Saltier (Parke-Davis Pharmaceutical Re-
search Division, Ann Arbor, MI). NIH-3T3IR cells transfected with the
C12S (dn) mutant gene for LMW-PTP (dnNIH-3T3IR) were prepared as
described previously (16) and routinely cultured in Dulbecco’s modified
Eagle’s medium containing with 10% fetal calf serum and 75 units/ml
hygromycin, in 5% CO2 humidified atmosphere.
Pervanadate Treatment, Preparation of Lysates, and in Vitro Dephos-
phorylation Experiments—Prior to cell lysis, 80–90% confluent cultures
of cells (NIH-3T3 fibroblasts and H-end endothelial cells) were treated
for 30 min with 0.1 mM pervanadate (20 ml of a fresh solution containing
50 mM sodium orthovanadate and 50 mM H2O2 was added to 10 ml of
medium). Cells were collected and then lysed with 20 mM Tris-HCl
buffer, pH 7.4, containing 1 mM EDTA, 0.1 M NaCl, 1% Triton X-100,
10% glycerol, 1 mM phenylmethanesulfonyl fluoride, 1 mg/ml aprotinin,
1 mg/ml leupeptin, and 5 mM iodoacetate. Iodoacetate was added in
order to inactivate irreversibly all intracellular PTPs (all members of
PTP family contain an active site essential cysteine residue; Ref. 13).
After incubation at 4 °C for 30 min, 10 mM dithiothreitol was added to
inactivate any unreacted iodoacetic acid, and the insoluble material
was removed by centrifugation at 102,000 3 g for 40 min. Lysates of
pervanadate-treated cells (1.5–3.5 mg of protein/ml) containing tyro-
sine-phosphorylated proteins were incubated at 25 °C in the absence or
presence of LMW-PTP or PTP-1B (0.05–0.1 mM final concentration).
Aliquots were removed at various times for analysis by SDS-PAGE and
anti-phosphotyrosine immunoblotting.
Detergent-free Purification of Caveolin-rich Membrane Fractions—
Low density caveolae-enriched domains were isolated as described by
Song et al. (24). Briefly, one confluent 100-mm dish, washed twice with
ice-cold phosphate-buffered saline (10 mM sodium phosphate and 0.15 M
NaCl, pH 7.2), was scraped into 0.5 ml of sodium carbonate buffer (500
mM sodium carbonate, pH 11, 25 mM MES, 150 mM NaCl, 1 mM phe-
nylmethanesulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin).
Cells were homogenized extensively using a Dounce homogenizer (50
strokes). The homogenate was then adjusted to 45% sucrose by the
addition of 0.65 ml of 80% sucrose in 25 mM MES, 150 mM NaCl, 1 mM
phenylmethanesulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin,
and placed at the bottom of an ultracentrifuge tube. A 5–35% discon-
tinuous sucrose gradient was formed above the 45% layer, by adding 2.5
ml of 35% sucrose and 1.3 ml of 5% sucrose, both in 250 mM sodium
carbonate, pH 11, 25 mM MES, 150 mM NaCl, 1 mM phenylmethane-
sulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin. The gradient
was centrifuged at 170,000 3 g for 20 h using a Beckman SW50.1 rotor.
For the analysis of the resulting gradient, 0.35-ml fractions were col-
lected from the top to the bottom of the gradient. The insoluble pellet
(fraction 15) was dissolved into 50 ml of Laemmli sample buffer. West-
ern blot analysis was performed using both anti-caveolin and anti-
LMW-PTP antibodies.
Immunoprecipitation Experiments—Confluent NIH-3T3 cells overex-
pressing C12S dnLMW-PTP cultured in 100-mm dishes were washed
with phosphate-buffered saline, lysed in ice-cold lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 60 mM n-octylglucoside, 2
mM EDTA, 1 mM orthovanadate, 100 mM NaF, 1 mM phenylmethane-
sulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin), and insoluble
material was removed by centrifugation at 10,000 3 g for 10 min.
Lysate (500 mg of protein) was incubated overnight with 1 mg of anti-
caveolin antibody or 1 mg of anti-LMW-PTP antibody. After a 1-h
incubation with protein A-Sepharose beads at 4 °C, the immunocom-
plexes were collected and washed extensively (three times) with lysis
buffer. The beads were suspended in 20 ml of 2-fold concentrated
Laemmli electrophoresis buffer (without 2-mercaptoethanol), separated
by SDS-PAGE, and electroblotted onto polyvinylidene difluoride mem-
branes for detection.
RESULTS
LMW-PTP Dephosphorylates Tyrosine-phosphorylated
Caveolin and Few Other Tyrosine-phosphorylated Proteins
Contained in Pervanadate-treated Cell Lysates—We have
treated both NIH-3T3 and H-end cells with pervanadate and
found that protein tyrosine phosphorylation was dramatically
enhanced with respect to untreated cells, which contain virtu-
ally undetectable levels of phosphotyrosine (25). Other authors
have previously reported similar findings using different cell
lines (26, 27); the enhancement of tyrosine phosphorylation is
due to the inhibition of all cellular PTPs by pervanadate. We
have performed time-course dephosphorylation experiments by
incubating lysates from pervanadate-treated H-end cells with
LMW-PTP. Aliquots of the incubation mixtures were with-
drawn at various times and analyzed by Western blotting with
anti-phosphotyrosine antibodies (PY20). Fig. 1A shows the
SDS-PAGE analysis, and Fig. 1B reports the densitometric
profiles of lanes 1–4 of panel A. LMW-PTP rapidly dephospho-
rylates a group of low molecular mass bands (,30 kDa), and at
least two additional bands in the 38–55-kDa range. Other
phosphotyrosine-containing proteins were also dephosphoryl-
ated, but more slowly. A similar pattern was observed using
lysates from pervanadate-treated NIH-3T3 cells (data not
shown).
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In order to verify the specificity of LMW-PTP in comparison
with other tyrosine phosphatases, we carried out the same
experiment on the cell lysate using PTP1B instead of LMW-
PTP. The result is reported in Fig. 1C; PTP1B has the capacity
to dephosphorylate a broad range of tyrosine-phosphorylated
protein substrates.
Taking into account the findings of Vepa et al. (27), who
demonstrated that caveolin is the highest phosphorylated pro-
tein with low molecular weight in pervanadate-treated endo-
thelial cells, we performed enzymatic dephosphorylation of
caveolin immunoprecipitated from the H-end cell lysate. The
samples were incubated for different times with LMW-PTP.
Western blot analyses performed respectively with anti-phos-
photyrosine (PY-20) and anti-caveolin (sc-894) antibodies re-
veal that LMW-PTP rapidly dephosphorylates phosphocaveolin
(Fig. 2A). We have also tested the activity of the phosphoty-
rosine-protein phosphatase PTP-1B on the anticaveolin immu-
noprecipitate. As expected, this enzyme dephosphorylates
phosphocaveolin (Fig. 2B) in agreement with the finding of Fig.
1C, which shows that PTP-1B displays broad substrate
specificity.
LMW-PTP Associates with Caveolae-enriched Membrane Do-
mains in Vivo and Coimmunoprecipitates with Caveolin—The
rationale of the following experiments, performed on NIH-3T3
fibroblasts overexpressing wild type or dominant negative
LMW-PTPs, is to demonstrate both the localization of LMW-
PTP in caveolae and to investigate the mechanism of its re-
cruitment into these membrane domains. We lysed confluent
cells and then separated the caveolae-enriched membrane do-
mains from other cellular components, using the density gra-
dient centrifugation technique described under “Experimental
Procedures.” Fifteen fractions were collected from the top of the
gradient, and the localization of LMW-PTP and caveolin was
performed by Western blotting. Fig. 3 (A and B) show that both
wild type and dnLMW-PTP molecular forms are distributed in
different gradient fractions; they colocalize with caveolin (frac-
tions 4 and 5), the caveolae domain marker protein, but they
are also present in fractions 12–14 (the loading zone), and in
the pellet (fraction 15). In fraction 1 of the density gradient
relative to the dnLMW-PTP-overexpressing cells, we have de-
tected a positive reaction with anti-LMW-PTP antibody. The
localization of both wt and dn LMW-PTPs in caveolae suggests
that a completely functional active site is not required for the
recruitment of the enzyme into caveolae. The LMW-PTP local-
ization in the pellet and in the loading zone was expected, since
previous papers reported that LMW-PTP is localized in both
cytoplasmic and cytoskeleton-associated fractions of NIH-3T3
cells (see Ref. 19, and citations therein).
To further investigate the association of LMW-PTP with
caveolin, we performed immunoprecipitation experiments with
anti-LMW-PTP antibody on lysates from NIH-3T3 cells over-
expressing wild type or dnLMW-PTP. Western blot analyses of
the immunoprecipitate using anti-caveolin (sc-894), anti-phos-
phocaveolin (PY-14), and anti-LMW-PTP antibodies (Fig. 3C)
demonstrated that cellular LMW-PTP and caveolin co-immu-
noprecipitate, indicating that they interact in these cells. Fur-
thermore, the formation of LMW-PTP-caveolin complexes does
not depend on caveolin phosphorylation, since we have not
observed a positive reaction with the PY-14 anti-phosphocaveo-
lin antibody. This suggests that a site different from the active
FIG. 1. LMW-PTP dephosphorylation of some phosphoty-
rosine-containing proteins from pervanadate-treated H-end cell
lysate. A, lysates from pervanadate-treated H-end cells were incubated
at 25 °C and pH 7.4 in the absence (2) or in the presence (1) of
LMW-PTP. At various times (0, 2, 4, 8, 12, 20, and 30 min), aliquots
containing 20 mg of protein were removed and subjected to SDS-PAGE/
Western blot analysis with PY-20 anti-phosphotyrosine antibody. B),
densitometric profiles of the immunoblots shown in A. Profiles 1, 2, 3,
and 4 correspond to 0, 2, 4, and 8 min, respectively. C, an experiment
similar to that shown in A was performed using PTP-1B instead of
LMW-PTP. Similar results were obtained in at least three separate
experiments.
FIG. 2. Dephosphorylation of immunoprecipitated caveolin by
LMW-PTP. Cell lysates from H-end cells were treated with sc-894
anti-caveolin antibody. The immunocomplex was collected on protein
A-Sepharose, and then washed extensively with lysis buffer. Beads
were suspended in 20 mM Tris-HCl buffer, pH 7.4, containing 2 mM
EDTA, and incubated in the absence (2) or in the presence (1) of
LMW-PTP. The incubation was performed at 25 °C. At various times (0,
1, 3, 5, 10, and 15 min), identical aliquots were removed and subjected
to SDS-PAGE/Western blot analysis with PY-20 anti-phosphotyrosine
and sc-894 anticaveolin antibodies. B, the same experiment was per-
formed with PTP-1B instead of LMW-PTP. IP, immunoprecipitation;
WB, Western blotting. Similar results were obtained in at least three
separate experiments.
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site of LMW-PTP could be involved in the binding with
caveolin.
Tyrosine-phosphorylated Caveolin Is a Cellular Substrate of
LMW-PTP—The results described above suggest that tyrosine-
phosphorylated caveolin is a potential substrate for LMW-PTP.
In order to demonstrate this hypothesis, we have performed
experiments with cells overexpressing both the insulin receptor
and the dominant negative C12S LMW-PTP mutant.
Insulin-stimulated and non-stimulated cells (neoNIH-3T3IR
and dnNIH-3T3IR) were lysed, and Western blots with anti-
phosphotyrosine (PY-20), anti-phosphocaveolin (PY-14), and
anti-caveolin (sc-894) antibodies were performed. As expected,
the main effect of insulin stimulation of neo cells is an in-
creased phosphorylation level of the 90-kDa insulin receptor
b-subunit (Fig. 4A, lanes 1 and 2). Insulin stimulation of NIH-
3T3IR cells overexpressing dnLMW-PTP causes a dramatic
increase of tyrosine phosphorylation of the insulin receptor
with respect to control cells (Fig. 4A, lanes 3 and 4). The
overexpression of dnLMW-PTP is accompanied by a slight in-
crease in the phosphorylation level of another band of approx-
imately 60 kDa. The anti-caveolin Western blot shows that
caveolin is present in the lysates (Fig. 4C), but the PY-20
antibody does not reveal phosphorylated caveolin (Fig. 4A).
Nevertheless, Western blot analysis performed with the mono-
clonal antibody PY-14 (which recognizes Tyr14-phosphorylated
caveolin with high specificity) shows that upon insulin treat-
ment caveolin phosphorylation is strongly enhanced in neo-
NIH-3T3IR cells, indicating that a tyrosine kinase activated
upon insulin-signaling is involved (Fig. 4B, lanes 1 and 2). The
overexpression of the dominant negative LMW-PTP causes an
increase in caveolin phosphorylation level both in untreated
and in insulin-stimulated cells as compared with the control
cells (Fig. 4B). Moreover, we demonstrated that, in these cells,
caveolin coimmunoprecipitates with LMW-PTP (Fig. 4, panels
D–F), and that the amount of immunoprecipitated caveolin is
not dependent on its phosphorylation. In the control cells,
immunoprecipitation with the anti-LMW-PTP antibody does
not result in detectable LMW-PTP levels (Fig. 4F, lanes 1 and
2). Nonetheless, the samples contain significant amounts of
immunoprecipitated caveolin (Fig. 4D). We think that this is
due to the low basal level of LMW-PTP in control cells; in
contrast, caveolin is revealed in the immunoprecipitate be-
cause it forms homooligomers (31), which may interact with
other proteins with an unknown stoichiometry.
Taken together, the above experiments clearly demonstrate
that the overexpression of the C12S LMW-PTP mutant in
NIH-3T3IR cells causes the enhancement of the tyrosine phos-
phorylation of some specific proteins (such as insulin receptor
b-subunit and caveolin) because it protects them against the
action of cellular PTPs. Some authors have described these
kinds of mutant as substrate traps, since, although they are
catalytically inactive, they maintain the capacity to bind sub-
strates, thus protecting them from dephosphorylation (28–30).
The insulin receptor, which is immediately phosphorylated
upon insulin stimulation, is an already known physiological
substrate of LMW-PTP (16); our results suggest that caveolin,
which is phosphorylated on tyrosine by a kinase activated upon
insulin signaling, is a potential new cellular substrate for
LMW-PTP.
DISCUSSION
The cellular level of protein phosphotyrosine is generally
very low (25). In order to elevate cellular tyrosine phosphoryl-
ation, two approaches are currently used. First, physiological
FIG. 3. LMW-PTP associates with
caveolae membranes in vivo and coim-
munoprecipitates with caveolin. De-
tergent-free sodium carbonate-based ly-
sates were prepared from NIH-3T3 cells
overexpressing wt (A) or dn (B) LMW-PTP,
and fractionated by flotation in sucrose
density gradient. Fractions of 0.35 ml were
collected from the top to the bottom of the
gradient. Aliquots (20 ml) of the fractions
were subjected to SDS-PAGE/Western blot
analysis with anti-LMW-PTP and sc-894
anti-caveolin antibodies. C, cell lysates
from NIH-3T3 cells overexpressing wt or
dn LMW-PTP were treated with anti-
LMW-PTP antibody, and the immunopre-
cipitated proteins were analyzed by SDS-
PAGE/Western blot analysis using anti-
caveolin (sc-894), anti-phosphocaveolin
(PY-14), and anti-LMW-PTP antibodies.
IP, immunoprecipitation; WB, Western
blotting. Similar results were obtained in
at least three separate experiments.
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stimulation of cells with growth factors, which trigger cascades
of tyrosine phosphorylation events, results in tyrosine phospho-
rylation of only a limited number of proteins; second, treatment
of cells with pervanadate to inhibit intracellular PTPs results
in the phosphorylation of a large number of proteins. We have
used the latter method to obtain cell lysates and immunopre-
cipitates useful for revealing the tyrosine-phosphorylated pro-
teins that are rapidly dephosphorylated by LMW-PTP in vitro.
We performed time-course dephosphorylation experiments re-
vealing tyrosine-phosphorylated proteins by immunoblot anal-
ysis with the PY-20 antibody. Our findings indicate that the
LMW-PTP dephosphorylates some bands very rapidly, whereas
it dephosphorylates other bands only after longer incubation
periods.
Since Vepa et al. (27) reported that caveolin is one of the most
tyrosine-phosphorylated proteins in pervanadate-treated endo-
thelial cells, we performed immunoprecipitation of caveolin
species using anti-caveolin antibody. The incubation of this
immunoprecipitate with LMW-PTP and the successive immu-
noblot analyses using both anti-phosphotyrosine and anti-
caveolin antibodies demonstrated that LMW-PTP very rapidly
dephosphorylates phosphocaveolin in vitro. Furthermore, both
immunoprecipitation experiments with anti-LMW-PTP or anti-
caveolin antibodies and cellular fractionation experiments in
wtNIH-3T3 or dnNIH-3T3 cells demonstrated that LMW-PTP
is associated with caveolin in caveolae membrane enriched
domains in vivo. Moreover, we have demonstrated that this
interaction does not require caveolin phosphorylation (Fig. 3C);
instead, it is in all probability mediated by a LMW-PTP se-
quence motif similar to those found in other caveolin-binding
proteins. In fact, Couet et al. (5), using the caveolin scaffolding
domain to select random peptide ligands from phage display
libraries, proposed the following caveolin-binding motifs:
cXcXXXXc or cXXXXcXXc (where c is an aromatic residue
and X is any amino acid). Interestingly, in that study, nearly
10% of the selected 15-mer peptides contained only two aro-
matic residues. The authors also reported that, although a
caveolin consensus motif including four aromatic residues
(cXcXXXXcXXc) has been identified in several Ga subunits,
Gaq uses valine and leucine as substitutions for two of these
aromatic residues. Despite this substitution, Gaq has been
shown to coimmunoprecipitate with caveolin. Thus, it seems
possible that caveolin-binding requirements are broader than
described previously. Recently, the caveolin-binding sequences
of other caveolin-binding proteins have been described. Car-
man et al. (32) have reported that all known G-protein-coupled
receptor kinases contain the conserved caveolin-binding motif
(I/L)XXXXFXXF. We have observed that this caveolin-binding
motif is also present in LMW-PTP (residues 77–85) (33), sug-
gesting that caveolin interacts with this LMW-PTP region.
There is increasing evidence that caveolae play a major role
in organizing signal transduction at the cell surface (3, 34).
Different hormone receptors and signal transducers are local-
ized in caveolae, and specific signaling events originate in
caveolae, including the EGF-dependent activation of Raf-1 (35),
interleukin-1b-stimulated production of ceramide (36), and
PDGF receptor kinase cascade (37). Furthermore, caveolin-1 is
directly involved in the modulation of the activity of heterotri-
meric GTP-binding proteins in vitro (38). Thus, caveolae may
be involved in the organization of these molecules, a necessary
step for the integration of different sources of information
during signal transduction.
Caveolin-1 exists in vivo as two molecular species (a and b)
that differ in their NH2-terminal sequences. These two species
derive from a single gene through alternate initiation during
translation; a-caveolin contains residues 1–178, whereas
b-caveolin contains residues 32–178. Li et al. (6) have demon-
strated that only a-caveolin is phosphorylated by v-Src in vitro
and in vivo, and Ko et al. (39) detected tyrosine phosphorylation
only in the b-isoform of caveolin in the Rat-1 cell line express-
ing a temperature-sensitive pp60v-src kinase. Tyrosine phos-
phorylation of caveolin has also been detected in normal cells,
but appears to occur in a strictly regulated fashion. For exam-
ple, insulin stimulates tyrosine phosphorylation of caveolin-1
only in fully differentiated 3T3-L1 adipocytes but not in fibro-
blasts (preadipocytes), despite the fact that both cell types
express caveolin-1 and active insulin receptors (7, 40). The
functional consequences of tyrosine phosphorylation of caveo-
lin-1 are not known. However, several reports suggest some
cellular implications of caveolin phosphorylation. For example,
tyrosine phosphorylation of caveolin-1 has been linked to cell
transformation by v-Src (41, 42). Koleske et al. (43) reported
that cells transformed by oncogenes show reduced levels of
caveolin-1 along with attenuated number of caveolae. Lee et al.
(44) found that overexpression of caveolin-1 in oncogenically
transformed cells and in breast cancer cells, where the expres-
sion of caveolin-1 is largely reduced, resulted in substantial
growth inhibition and attenuation of anchorage-independent
growth in soft agar. Recently, Kim et al. (45) reported that
COOH-terminal truncation and/or overexpression of the EGF
receptor in B82L fibroblasts can induce an enhanced tyrosine
phosphorylation of caveolin-1 in response to EGF, suggesting
that caveolin-1 plays an important role in the EGF signaling
events that are mediated by aberrant forms or levels of EGF
receptor. An enhanced level of wild type EGF receptor was
detected in various human cancers (46, 47) and was linked with
cell transformation (48–50). Furthermore, truncated EGF re-
FIG. 4. Effect of insulin stimulation on the association of en-
dogenous tyrosine-phosphorylated caveolin with transfected
dnLMW-PTP in NIH-3T3IR cells. cDNAs encoding C12S dominant
negative (dn) mutant of LMW-PTP or the vector alone (neo) were
transfected in NIH-3T3IR cells. Cells were stimulated (1) or not (2)
with insulin (100 nM) for 5 min, and lysates were analyzed by SDS-
PAGE/Western blotting with PY-20 anti-phosphotyrosine antibody (A),
with PY-14 anti-phosphocaveolin antibody (B), and with sc-894 anti-
caveolin antibody (C). Aliquots of the lysates from the above cell lines
were treated with the anti-LMW-PTP antibody, and the immunopre-
cipitated proteins were analyzed by SDS-PAGE/Western blotting with
sc-894 anti-caveolin (D), PY-14 anti-phosphocaveolin (E), and anti-
LMW-PTP (F) antibodies. IP, immunoprecipitation; WB, Western blot-
ting. The results are representative of three independent experiments.
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ceptors that lack COOH-terminal autophosphorylation sites
can also induce mitogenesis and cell transformation (51–54).
Among other possible effects, tyrosine phosphorylation of
caveolin-1 may alter cholesterol binding to the caveolae and
membrane structure (39). In fact, several studies have demon-
strated that caveolin-1 is a cholesterol-binding protein (55) and
that cholesterol is an important component of caveolae. Fur-
thermore, the observed traffic of caveolin-1 between the endo-
plasmic reticulum and the Golgi apparatus has been implicated
in the transport of cholesterol to caveolae (56). Taking into
account that cholesterol level of the caveolae membrane may be
involved in the regulation of mitogenesis, tyrosine phosphoryl-
ation of caveolin-1 may improve the transport of cholesterol,
determining a loss of this important component in the caveolae,
and thereby altering their structure/function, with consequent
effects on cell growth control (45).
In the present study, using a monoclonal antibody highly
specific for tyrosine-phosphorylated caveolin (PY-14) (57, 58),
we have shown that the overexpression of the dn mutant of
LMW-PTP (an inactive form able to bind its substrates) in
NIH-3T3IR cells causes the enhancement of tyrosine-phospho-
rylated caveolin levels. This effect is produced by the protection
exerted by dnLMW-PTP against the dephosphorylating action
of endogenous LMW-PTP and other cellular PTPs on tyrosine-
phosphorylated caveolin. Insulin stimulation causes a dra-
matic increase of the amount of phosphocaveolin level in the
dnNIH-3T3IR cells with respect to neo NIH-3T3IR cells, dem-
onstrating that phosphorylated caveolin is a cellular target for
LMW-PTP.
Eukaryotic cells contain a very large number of different
PTPs that probably act specifically on different cellular sub-
strates and in different cellular sites. The identification of the
physiological substrates of PTPs is a key element in under-
standing the biological function of this family of enzymes.
Taken together, our results on the localization of LMW-PTP in
caveolae, on the in vivo interaction between LMW-PTP and
caveolin, and on the capacity of this enzyme to rapidly dephos-
phorylate phosphocaveolin indicate that tyrosine-phospho-
rylated caveolin is a relevant substrate for LMW-PTP. We
suggest that this enzyme is a good candidate for the cellular
regulation of phosphorylated caveolin level, with consequent
implications in all the processes that are affected by caveolin
phosphorylation on tyrosine.
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